Osborne Clarke advised Vitestro Holding B.V. in its EUR 12 million Series A financing Round led by California based investor Sonder Capital Advisors, LLC, alongside existing investors and new private investors with experience in the clinical laboratory and MedTech industry.
Vitestro is an Utrecht, Netherlands-based developer of autonomous blood drawing devices. Vitestro's device combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. A prototype has been tested on more than 1,000 patients. Clinical studies will continue in 2023, with European market introduction anticipated in 2024.
The Osborne Clarke team assisting Vitestro included Partner Herke van Hulst, associate Nick Staes and our Notary Cars-Jan van Gool and associate Eveline Leijen.
Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and MedTech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms and the biggest pharma and medical devices companies in the market.